Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of New Isoniazid 300mg Formulation vs Reference 100mg in Healthy Volunteers
NCT02043314Phase 1Completed
- Sponsor
- Fundação Oswaldo Cruz
- Start
- Oct 2008
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of isoniazid in Tuberculosis (TB) (2 arms), sponsored by Fundação Oswaldo Cruz. Primary endpoint: Average bioequivalence based on the 90% CI up to 6 months. Started Oct 2008; status: completed.
02
Drugs
isoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02043314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043314.